Woojin B&G Begins Development of Therapeutics and Vaccines for Feline Infectious Diseases
Woojin B&G, a company specializing in veterinary pharmaceuticals, has officially launched the development of therapeutics and vaccines for feline infectious diseases and is expanding its global research collaborations.
On March 24, Woojin B&G announced that it is pursuing the development of pharmaceuticals to address feline infectious peritonitis (FIP) and zoonotic diseases transmitted via cats.
The company recently signed memorandums of understanding (MOUs) for research collaboration with Yamaguchi University College of Veterinary Medicine, Gadjah Mada University College of Veterinary Medicine, and Hanoi University College of Veterinary Medicine, establishing a global cooperation system for joint research.
This collaboration is considered significant as it enables the company to secure overseas clinical trials and a disease monitoring network for the development of feline infectious disease therapeutics and vaccines. In particular, these universities possess high levels of expertise in infectious disease research and veterinary clinical studies in Southeast Asia and Japan, and are expected to play a crucial role in conducting clinical trials and epidemiological analysis based on naturally occurring feline patients.
Woojin B&G plans to work with animal hospitals and research institutions affiliated with each university to conduct clinical trials based on naturally occurring FIP cases, and to establish a research system allowing for rapid verification of the safety and efficacy of vaccine and therapeutic candidates for cats in accordance with international standards.
Southeast Asia, where the companion animal population is increasing and various infectious disease cases are being reported, is regarded as an important hub for clinical studies of pet pharmaceuticals and epidemiological research on infectious diseases.
Based on this global cooperation network, the company plans not only to develop FIP therapeutics but also to gradually expand its research into vaccines for zoonotic diseases such as severe fever with thrombocytopenia syndrome (SFTS).
A company official stated, "There are limitations to conducting clinical trials for cats domestically. By collaborating with leading overseas veterinary colleges, we plan to accelerate clinical validation of therapeutics and vaccines, and lay the foundation for entering the global companion animal pharmaceutical market."
Meanwhile, Woojin B&G has fully repaid the outstanding amount of 5.6 billion won from its 5th convertible bonds (CB) that matured this month. This repayment was made using existing cash and internal funds, which not only strengthens the company’s financial stability by resolving related debts, but also addresses concerns over dilution of existing shareholders' equity that could have resulted from possible conversion of the bonds into shares.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
The company official added, "We are continuing to improve our financial structure based on recent performance improvements and stable cash flow. Moving forward, we aim to grow into a global leader in the development of veterinary pharmaceuticals."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.